Modality
Radioligand
MOA
CDK4/6i
Target
BCL-2
Pathway
Neuroinflam
MCL
Development Pipeline
Preclinical
~Jun 2016
→ ~Sep 2017
Phase 1
Dec 2017
→ Feb 2025
Phase 1Current
NCT06317396
605 pts·MCL
2017-12→2025-02·Active
605 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-02-131.1y agoPh2 Data· MCL
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2
P1/2
Active
Catalysts
Ph2 Data
2025-02-13 · 1.1y ago
MCL
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06317396 | Phase 1/2 | MCL | Active | 605 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| RHH-1969 | Roche | Approved | BET | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| VRT-5441 | Vertex Pharma | Phase 3 | GLP-1R | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-4339 | Argenx | Phase 2 | BCL-2 |